Metformin Eql (Metformin Hydrochloride)

Metformin Eql belongs to the biguanide class and is employed in the management of disorders related to impaired glucose regulation.

• Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels.
• Prediabetes: helps normalize fasting glucose and delays progression to overt diabetes.
• Metabolic syndrome: enhances insulin sensitivity and may aid in weight management.

• Metformin reduces hepatic gluconeogenesis by activating AMP‑activated protein kinase (AMPK), which decreases glucose production. It also improves peripheral insulin sensitivity by enhancing glucose uptake in muscle and adipose tissue, and modestly reduces intestinal glucose absorption, collectively lowering blood glucose levels without stimulating insulin secretion.

Metformin Eql may be associated with a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools.
• Abdominal discomfort: cramping or pain.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight.
• Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic disturbance.
• Severe hypoglycaemia: when combined with insulin or secretagogues.
• Hepatic dysfunction: elevated liver enzymes.
• Skin rash or hypersensitivity: including Stevens‑Johnson syndrome.
• Persistent gastrointestinal bleeding.
• Acute pancreatitis: very uncommon.

When prescribing Metformin Eql, clinicians should consider several safety factors.

• Renal function: assess eGFR before initiation and periodically thereafter.
• Hepatic disease: use with caution in patients with liver impairment.
• Alcohol consumption: avoid excessive intake to reduce lactic acidosis risk.
• Risk of lactic acidosis: monitor for unexplained fatigue, myalgia, dyspnoea.
• Pregnancy and lactation: evaluate benefits versus risks with the prescriber.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Eql can interact with various medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk.
• Cimetidine: can raise metformin plasma concentrations.
• Nucleoside reverse transcriptase inhibitors: may potentiate metformin exposure.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• Diuretics: can affect renal clearance of metformin.
• ACE inhibitors/ARBs: monitor renal function and electrolytes.
• Corticosteroids: may increase blood glucose, requiring dose adjustment.